<DOC>
	<DOCNO>NCT00503347</DOCNO>
	<brief_summary>This trial design assess safety , tolerability , pharmacokinetics viral kinetics multiple infusion bavituximab patient co-infected HCV HIV .</brief_summary>
	<brief_title>Bavituximab Repeat-Dose Trial Patients Co-Infected With Chronic Hepatitis C Virus Human Immunodeficiency Virus</brief_title>
	<detailed_description>OBJECTIVES : - To determine safety tolerability bavituximab administer multiple intravenous ( IV ) infusion patient co-infected HCV HIV - To characterize pharmacokinetic profile viral kinetics multiple intravenous infusion bavituximab patient infected HCV HIV - To define maximum tolerate dose ( MTD ) and/or maximum effective dose ( MED ) bavituximab administer multiple infusion patient infect chronic HCV infection HIV</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written inform consent obtain Adults 18 year age old HIV infection document detectable HIV RNA PCR Absolute CD4+ &gt; 300 cells/mm3 Chronic hepatitis C infection base history detectable serum HCV RNA Serum alanine aminotransferase ( ALT ) normal limit and/or historical biopsy consistent hepatitis C Complete blood count within normal limit Normal renal function ( serum creatinine within normal limit ) PT/INR aPTT within normal limit All patient reproductive potential must agree use approved form barrier contraception agree become pregnant take study medication 30 day study completion . Female patient must negative serum pregnancy test prestudy ( applicable patient bilateral oophorectomy and/or hysterectomy patient postmenopausal ) HCV HIV antiviral therapy within 4 week Day 0 Prior exposure chimeric antibody Any cause liver disease chronic hepatitis C , autoimmune alcoholic liver disease . Decompensated clinical liver disease , include history prolong clot time , hypoalbuminemia , encephalopathy , treatment elevate ammonia level , ascites Any evidence clinically significant bleeding define gross hematuria , hemoptysis , gastrointestinal bleeding Known history bleed diathesis coagulopathy ( e.g. , von Willebrand Disease Hemophilia ) Any history thromboembolic event [ e.g. , deep vein thrombosis ( DVT ) pulmonary thromboembolism ( PE ) ] . A history include central venous catheterrelated thrombosis acceptable documentation resolution least 12 month prior enrollment . Concurrent therapy oral parenteral anticoagulant Concurrent hormone therapy ( i.e. , estrogen contraceptive , hormone replacement , antiestrogen ) Investigational therapy within 4 week Day 0 Major surgery within 4 week Day 0 Pregnant nursing woman Uncontrolled intercurrent disease ( e.g. , diabetes , hypertension , thyroid disease ) Any history angina pectoris , coronary artery disease cerebrovascular accident , transient ischemic attack A history condition require antiplatelet therapy exception general cardiovascular prophylaxis aspirin A history condition require treatment ( past current ) coumarintype agent Cardiac arrhythmia require medical therapy Serious nonhealing wound ( include wound heal secondary intention , ulcer , bone fracture ) Requirement chronic daily treatment NSAIDs , antiplatelet drug ( e.g. , phosphodiesterase inhibitor , adenosine diphosphate receptor antagonist ) , steroids Cancer , autoimmune disease disease concurrent therapy know cause significant alteration immunologic function . Corticosteroids administer pretreatment , treat adverse event , allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>coinfection chronic hepatitis C virus HIV</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>